|
Diffuse Intrinsic Pontine Glioma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
There was no significant difference in EZH2 expression between the K27M mutant and wild-type DIPGs.
|
31848724 |
2020 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Global characterization of proteome and lysine methylome features in EZH2 wild-type and mutant lymphoma cell lines.
|
31846764 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
EZH2, a methyltransferase specifically trimethylates the lysine 27 of histone H3 and its aberrance in several cancers promotes the development of its inhibitors against hematological tumors.
|
31846764 |
2020 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
EZH2, a methyltransferase specifically trimethylates the lysine 27 of histone H3 and its aberrance in several cancers promotes the development of its inhibitors against hematological tumors.
|
31846764 |
2020 |
|
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Global characterization of proteome and lysine methylome features in EZH2 wild-type and mutant lymphoma cell lines.
|
31846764 |
2020 |
|
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Global characterization of proteome and lysine methylome features in EZH2 wild-type and mutant lymphoma cell lines.
|
31846764 |
2020 |
|
Endometrial Carcinoma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
We investigated patterns of EZH2 expression in endometrial cancer.
|
31843273 |
2020 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Enhancer of zeste homolog 2 (EZH2) is a histone methyl transferase that mediates epigenetic silencing of tumor suppressor genes.
|
31843273 |
2020 |
|
Malignant neoplasm of endometrium
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
We investigated patterns of EZH2 expression in endometrial cancer.
|
31843273 |
2020 |
|
Neural Tube Defects
|
0.010 |
Biomarker
|
group |
BEFREE |
This study established the role of transcription factor Sox19b and epigenetic factor EZH2 regulatory network on NSC development, which provides new clues and theoretical guidance for the clinical treatment of neural tube defects.
|
31842983 |
2019 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, EZH2 silencing resulted in inhibited glioma cell proliferation, invasion, and migration.
|
31842978 |
2019 |
|
Allergic rhinitis (disorder)
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The LncGAS5 in AR-EXO inhibited transcription and expression of EZH2, and it also inhibited T-bet expression at mRNA and protein levels.
|
31841965 |
2020 |
|
Osteoporosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
By conducting TF enrichment analyses, we identified EZH2 as a common TF binding to osteoporosis-associated enhancers, and EZH2 was also associated with BMD in a Chinese population.
|
31833556 |
2020 |
|
Diffuse Large B-Cell Lymphoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Degradation of PRC2 with UNC6852 blocks the histone methyltransferase activity of EZH2, decreasing H3K27me3 levels in HeLa cells and diffuse large B cell lymphoma (DLBCL) cells containing EZH2 gain-of-function mutations.
|
31831267 |
2020 |
|
Septicemia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Taken together, lncRNA MALAT1 interacting with EZH2 stimulated AKT-1 phosphorylation and decreased BRCA1 expression, consequently aggravating the progression of sepsis, highlighting a promising therapeutic option for sepsis.
|
31830649 |
2020 |
|
Sepsis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Taken together, lncRNA MALAT1 interacting with EZH2 stimulated AKT-1 phosphorylation and decreased BRCA1 expression, consequently aggravating the progression of sepsis, highlighting a promising therapeutic option for sepsis.
|
31830649 |
2020 |
|
Arteriosclerosis
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Subjected to overexpressed GAS5, overexpressed EZH2, or downregulated ABCA1, the Apolipoprotein E (ApoE)<sup>-/-</sup> mice with atherosclerosis showed increased total cholesterol (TC), free cholesterol (FC), cholesterol ester (CE), low-density lipoprotein (LDL) levels, aortic plaque, and lipid accumulation, accompanied by reduced high-density lipoprotein (HDL) level and cholesterol outflow.
|
31830648 |
2020 |
|
Atherosclerosis
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Subjected to overexpressed GAS5, overexpressed EZH2, or downregulated ABCA1, the Apolipoprotein E (ApoE)<sup>-/-</sup> mice with atherosclerosis showed increased total cholesterol (TC), free cholesterol (FC), cholesterol ester (CE), low-density lipoprotein (LDL) levels, aortic plaque, and lipid accumulation, accompanied by reduced high-density lipoprotein (HDL) level and cholesterol outflow.
|
31830648 |
2020 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our work will likely establish epigenetic regulator EZH2 as a novel therapeutic target for preventing CHIP progression and treating hematological malignancies with TP53 mutations.
|
31827082 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previously we demonstrated that polyphyllin I (PPI), a bioactive component extracted from Paris polyphylla, inhibited the growth of non-small cell lung cancer (NSCLC) cells through the SAPK/JNK-mediated suppressing p65, DNMT1 and EZH2 expressions.
|
31819506 |
2019 |
|
Lymphoma, Follicular
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Several EZH2 inhibitors, which inhibit the methyltransferase activity of EZH2, have shown promise in treating sarcoma and follicular lymphoma in clinics.
|
31819273 |
2020 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
EZH2 is overexpressed in multiple types of cancer including triple-negative breast cancer (TNBC), and high expression levels correlate with poor prognosis.
|
31819273 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
EZH2 is overexpressed in multiple types of cancer including triple-negative breast cancer (TNBC), and high expression levels correlate with poor prognosis.
|
31819273 |
2020 |
|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, EZH2 inhibitors are ineffective at blocking proliferation of TNBC cells, even though they effectively reduce the H3K27me3 mark.
|
31819273 |
2020 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, EZH2 inhibitors are ineffective at blocking proliferation of TNBC cells, even though they effectively reduce the H3K27me3 mark.
|
31819273 |
2020 |